1. LOC644656 promotes cisplatin resistance in cervical cancer by recruiting ZNF143 and activating the transcription of E6-AP.
- Author
-
Li M, Chen J, Zhang H, Zhang Y, Wang J, Shen Z, Chen Y, Hou W, and Chi C
- Subjects
- Female, Humans, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, RNA, Transcriptional Activation, Cisplatin therapeutic use, MicroRNAs metabolism, Trans-Activators metabolism, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms genetics, Drug Resistance, Neoplasm, Ubiquitin-Protein Ligases metabolism
- Abstract
Cisplatin resistance remains a persistent challenge in cervical cancer (CC) treatment. Molecular biomarkers have garnered attention for their association with cisplatin resistance in various diseases. Long non-coding RNAs (lncRNAs) exert significant influence on CC development. This study explores the role of LOC644656 in regulating cisplatin resistance in CC. Parental and cisplatin-resistant CC cells underwent cisplatin treatment. Functional assays assessed cell proliferation and apoptosis under different conditions. RNA pull-down with mass spectrometry, along with literature review, elucidated the interaction between LOC644656, ZNF143, and E6-AP. Mechanistic assays analyzed the relationship between different factors. RT-qPCR and western blot quantified RNA and protein levels, respectively. In vivo models validated E6-AP's function. Results revealed LOC644656 overexpression in cisplatin-resistant CC cells, exacerbating cell growth. LOC644656 recruited ZNF143 to activate E6-AP transcription, promoting cisplatin resistance in CC. In conclusion, LOC644656 positively modulates E6-AP expression via ZNF143-mediated transcriptional activation, contributing to cisplatin resistance in CC., Competing Interests: Declaration of competing interest No potential competing interest was reported by the authors., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF